Reuters logo
BRIEF-AbbVie presents long-term data on cancer drug Imbruvica at ASCO
2017年6月5日 / 上午11点12分 / 6 个月前

BRIEF-AbbVie presents long-term data on cancer drug Imbruvica at ASCO

June 5 (Reuters) - Abbvie Inc

* Long-term Imbruvica (Ibrutinib) efficacy and safety data at ASCO 2017 show sustained survival rates in up to four years in previously-treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients, including those with high-risk disease

* Abbvie Inc - ‍data show 59 percent progression free survival and 74 percent overall survival in CLL/SLL patients treated with Imbruvica​

* Abbvie - ‍91 percent of CLL/SLL patients treated with Imbruvica achieved a complete or partial response, with complete responses increasing over time​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below